Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia—a wise Liaison?

TP53mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis

(2013) Austin G. Kulasekararaj et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

(2012) M. A. Sekeres et al.   BLOOD

Aberrant methylation of the M-type phospholipase A2 receptor gene in leukemic cells

(2012) Mario Menschikowski et al.   BMC CANCER

Impact of lenalidomide on the functional properties of human mesenchymal stromal cells

(2012) Manja Wobus et al.   EXPERIMENTAL HEMATOLOGY

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia

(2012) D. A. Pollyea et al.   HAEMATOLOGICA

Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial

(2012) K. Sockel et al.   HAEMATOLOGICA

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Topography, Clinical, and Genomic Correlates of 5q Myeloid Malignancies Revisited

(2012) Andres Jerez et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML

(2012) G Ramsingh et al.   LEUKEMIA

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

(2012) A Kuendgen et al.   LEUKEMIA

Clinical Results With the DNA Hypomethylating Agent 5-Aza-2′-Deoxycytidine (Decitabine) in Patients With Myelodysplastic Syndromes: An Update

(2012) Tina E. Joeckel et al.   SEMINARS IN HEMATOLOGY

Allogeneic Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndromes

(2012) Uwe Platzbecker   SEMINARS IN HEMATOLOGY

Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes

(2012) Aristoteles A.N. Giagounidis   SEMINARS IN HEMATOLOGY

Lenalidomide in AML: Del(5q) or who?

(2011) D. P. Steensma et al.   BLOOD

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605

(2011) M. A. Sekeres et al.   BLOOD

Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis

(2011) A. Narla et al.   BLOOD

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

(2011) P. Fenaux et al.   BLOOD

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

(2011) L. Mollgard et al.   HAEMATOLOGICA

Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes

(2011) Rafael Bejar et al.   JOURNAL OF CLINICAL ONCOLOGY

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

(2011) Michael Lübbert et al.   JOURNAL OF CLINICAL ONCOLOGY

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

(2011) Martin Jädersten et al.   JOURNAL OF CLINICAL ONCOLOGY

Interest of the association azacitidine–lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype

(2011) E Scherman et al.   LEUKEMIA

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

(2011) D A Pollyea et al.   LEUKEMIA

Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study

(2011) Haifa K. Al-Ali et al.   LEUKEMIA & LYMPHOMA

Clinical Effect of Point Mutations in Myelodysplastic Syndromes

(2011) Rafael Bejar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid

(2011) Andrea Kuendgen et al.   Clinical Epigenetics

Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes

(2010) Mikkael A. Sekeres et al.   AMERICAN JOURNAL OF HEMATOLOGY

Advances in the 5q- syndrome

(2010) J. Boultwood et al.   BLOOD

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia

(2010) T. A. Fehniger et al.   BLOOD

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

(2010) R. Itzykson et al.   BLOOD

Azacitidine for the treatment of lower risk myelodysplastic syndromes

(2010) Pellegrino Musto et al.   CANCER

Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes

(2010) Mikkael A. Sekeres et al.   JOURNAL OF CLINICAL ONCOLOGY

Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission

(2010) Ramin Tehranchi et al.   NEW ENGLAND JOURNAL OF MEDICINE

CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT

(2009) C D Ford et al.   BONE MARROW TRANSPLANTATION

Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission

(2009) L Adès et al.   BONE MARROW TRANSPLANTATION

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells

(2009) C Flotho et al.   LEUKEMIA

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

(2009) S. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13

(2008) T. A. Fehniger et al.   BLOOD

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

(2008) L. Ades et al.   BLOOD

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML

(2008) Y. Jiang et al.   BLOOD

Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

(2008) Mikkael A. Sekeres et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype

(2008) C Haferlach et al.   LEUKEMIA

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

(2008) Benjamin L. Ebert et al.   NATURE